MorphoSys and Incyte Announce Five-Year Results of L-MIND St

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) 16.04.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this...

Related Keywords

Planegg , Bayern , Germany , University Hospital , Florida , United States , Massachusetts , Orlando , Delaware , Boston , Canada , American , Tim Demuth , Johannes Duell , Steven Stein , Practice Research Clinical Haematology , Twitter , American Association For Cancer Research Annual Meeting , Linkedin , Exchange Commission , Distribution Services , Nasdaq , Morphosys Us Inc , Xencor Inc , American Association For Cancer Research , Drug Administration , Incyte Announce Five Year Results , Showed Prolonged , Durable Responses , American Association , Cancer Research Annual Meeting , Cancer Research , Annual Meeting , Medical Clinic , Chief Research , Development Officer , Chief Medical Officer , Diffuse Largeb Cell Lymphoma , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Prescribing Information , Patient Information , Important Safety , Morphosy Annual Report , Practice Research , Corporate News , Regulatory Announcements ,